File No. X.11026/179/2020-BD
Government of India
Director General of Health Services
Central Drugs Standard Control organisation
(Biological Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Date:1st July 2020

Information on Convalescent Plasma in COVID-19

This is with reference to the CLINICAL MANAGEMENT PROTOCOL: COVID-19 issued by the Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services dated 27-06-2020 Version 4, wherein, certain therapies are indicated for use as investigational therapies, in which convalescent plasma by plasmapheresis has been indicated as "Off Label" in COVID-19 patients' stating that-

Convalescent plasma may be considered in patients with moderate disease who are not improving (oxygen requirement is progressively increasing) despite use of steroids. Special prerequisites while considering convalescent plasma include:

- ABO compatibility and cross matching of the donor plasma.
- Neutralizing titer of donor plasma should be above the specific threshold (if the latter is not available, plasma IgG titer (against S-protein RBD) above 1:640 should be used).
- Recipient should be closely monitored for several hours post transfusion for any transfusion related adverse events.
- Use should be avoided in patients with IgA deficiency or immunoglobulin allergy

Dose: Dose is variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hour.

The link for referring the details in the said guideline issued by the Government of India is as under.

https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19dated27062020.pdf